Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 8, 2000, Pages 2649-2659

  Shah, N ^a   Evans, W S ^a   Bowers, C Y ^b   Veldhuis, J D ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PRALMORELIN;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EFFECTOR CELL; ESTROGEN RESPONSIVE ELEMENT; FEEDBACK SYSTEM; FEMALE; GROWTH HORMONE RELEASE; HUMAN; MOLECULAR INTERACTION; POSTMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; PULSATILE FLOW; RANDOMIZED CONTROLLED TRIAL; RECEPTOR GENE; STIMULUS RESPONSE;

ADMINISTRATION, ORAL; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; GROWTH HORMONE-RELEASING HORMONE; HORMONES; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; INSULIN-LIKE GROWTH FACTOR I; LUTEINIZING HORMONE; MIDDLE AGED; OLIGOPEPTIDES; POSTMENOPAUSE; REGRESSION ANALYSIS;

EID: 0034457324     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.8.2649     Document Type: Article

References (74)

1. Effect of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro
2. Atypical growth hormone releasing peptides
3. Effects of estrogen and sex difference on secretion of human growth hormone
4. Fluctuations of human growth hormone secretion during menstrual cycle. Response to arginine
5. Studies of the sex-based variation of human growth hormone secretion
6. Hormonal relationships during the menstrual cycle
7. Gender differences in secretory activity of the human somatotropic (growth hormone) axis
8. Pathophysiology of the neuroregulation of GH secretion in experimental animals and the human
9. Structure-activity relationships of a synthetic pentapeptide that specifically releases GH in vitro
10. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
11. Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides
12. A receptor in pituitary and hypothalamus that functions in growth hormone release
13. Identification of a new G-protein-linked receptor for growth hormone secretagogues
14. Ghrelin is a growth-hormone-releasing acylated peptide from stomach
15. Cloning and characterization of the 5′-flanking region of the human growth hormone secretagogue receptor gene
16. The growth hormone response to hexarelin in children: Reproducibility and effect of sex steroids
17. Growth hormone releasing peptides
18. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations
19. Estradiol augments basal GH pulse mass and amplifies GH-secretory responsiveness to GHRP-2 (DAlaDβNalAlaTrpDPheLysNH2) in older women
20. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6
21. GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans
22. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: A phase I study in children
23. Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay
24. Differential impact of age, sexsteroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay
25. The pituitary gland secretes in bursts: Appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations
26. Specific methodological approaches to selected contemporary issues in deconvolution analysis of pulsatile neuroendocrine data
27. Twenty-four hour rhythms in plasma concentrations of adenohypophyseal hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts
28. Randomness and degrees of irregularity
29. Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males
30. Hormone pulsatility discrimination via coarse and short time sampling
31. The orderliness of the growth hormone (GH) release process and the mean mass of GH secreted per burst are highly conserved in individual men on successive days
32. Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release
33. Sexually dimorphic pattern of growth hormone secretion in the elderly
34. Females secrete growth hormone with more process irregularity than males in both human and rat
35. Differential orderliness of the GH release process in castrate male and female rats
36. Assessing temporal coupling between two, or among three or more, neuroendocrine pulse trains: Cross-correlation analysis, simulation methods, and conditional probability testing
37. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man
38. Estrogen and testosterone, but not a non-aromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: Evidence from pubertal pathophysiology and sex-steroid hormone replacement
39. Actions of estrogen on the pulsatile, nyctohemeral, and entropic modes of growth hormone secretion
40. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - A clinical research center study
41. Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the preovulatory interval in normal women
42. Effect of superovulation with human menopausal gonadotropins on growth hormone levels in women
43. Pulsatile growth hormone release in normal women during the menstrual cycle
44. Impact of estrogen on the dose-dependent inhibition by somatostatin of GH secretion in postmenopausal women
45. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotropic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth-hormone-releasing-hormone (GHRH) pulsatile infusion
46. Somatostatin infusion suppresses GH secretory burst number and mass in normal men: A dual mechanism of inhibition
47. An amplitude-specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentrations in men and premenopausal women
48. Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone (GH) secretion in prepubertal and late adolescent males and females
49. Operating behavior of dual or multiple endocrine pulse generators
50. GHRH and GHRP-2 interact to stimulate GH secretion in men in the presence of low-dose synthetic somatostatin (octreotide): Evidence for a novel collaboration between GHRH and GHRP
51. Synthetic somatostatin analog (octreotide) suppresses daytime growth hormone secretion equivalently in young and older men: Preserved pituitary responsiveness to somatostatin's inhibition in aging
52. Insulin-like growth factors (IGF) I and II and IGF binding proteins 1, 2 and 3 during low-dose growth hormone (GH) infusion and sequential euglycemic and hypoglycemic glucose clamps: Studies in GH-deficient patients
53. Marked effects of sustained low growth hormone (GH) levels on day-to-day fuel metabolism. Studies in GH deficient patients and healthy untreated subjects
54. Endogenous growth hormone secretion and clearance rates in normal boys as determined by deconvolution analysis: Relationship to age, pubertal status and body mass
55. Time-mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations rather than sex, estradiol, or menstrual-cycle stage primarily determine the GH elimination rate in healthy young women and men
56. Growth hormone (GH) responses to the hexapeptide GH-releasing peptide and GH-releasing hormone (GHRH) in the cynomolgus macaque: Evidence for non-GHRH-mediated responses
57. Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men
58. Augmentation of growth hormone secretion during puberty: Evidence for a pulse amplitude-modulated phenomenon
59. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep
60. Growth hormone-releasing and somatostatin concentrations in the hypophysial portal blood of conscious sheep during the infusion of growth hormone-releasing peptide-6
61. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man
62. Overview of human growth hormone: The roles of GHRH SST, and GHS-R in regulating GH release
63. Neuroendocrine control of growth hormone secretion
64. Maturation of the regulation of growth hormone secretion in young males with hypogonadotropic hypogonadism pharmacologically exposed to progressive increments in serum testosterone
65. Longitudinal changes in growth hormone secretory process irregularity assessed transpubertaly in healthy boys
66. A quantitative estimation of growth hormone secretion in normal man: Reproducibility and relation to sleep and time of day
67. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus
68. Physiological role of somatostatin on growth hormone regulation in humans
69. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: Potential involvement of endogenous somatostatin
70. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
71. Role of the new growth hormone-releasing secretagogues in the diagnosis of some hypothalamopituitary pathologies
72. Effects of sodium valproate and diazepam on β-endorphin, β-lipotropin and cortisol secretion induced by hypoglycemic stress in humans
73. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects
74. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure